Page last updated: 2024-10-24

positive regulation of neutrophil activation

Definition

Target type: biologicalprocess

Any process that activates or increases the frequency, rate or extent of neutrophil activation. [GOC:TermGenie, PMID:17588661]

Positive regulation of neutrophil activation is a complex process involving a cascade of signaling events that ultimately lead to the activation and recruitment of neutrophils to sites of inflammation or infection. This process is tightly regulated to ensure appropriate immune responses and prevent excessive inflammation.

**Key steps in positive regulation of neutrophil activation:**

1. **Signal Recognition:** Neutrophils possess a variety of receptors on their surface that can recognize and bind to a diverse range of stimuli including:
- **Pathogen-associated molecular patterns (PAMPs):** These are molecules specific to pathogens such as bacteria, viruses, fungi, and parasites. Examples include lipopolysaccharide (LPS) from bacteria, flagellin from bacteria, and dsRNA from viruses.
- **Damage-associated molecular patterns (DAMPs):** These are molecules released from damaged cells or tissues, indicating tissue injury. Examples include ATP, hyaluronic acid, and heat shock proteins.
- **Cytokines:** These are signaling molecules produced by other immune cells, particularly macrophages and T cells, that can activate neutrophils. Examples include TNF-α, IL-1β, and IL-8.

2. **Signal Transduction:** Upon recognition of a stimulus, the receptors on neutrophils initiate signaling cascades that involve a series of intracellular signaling molecules. This process typically involves:
- **Activation of tyrosine kinases:** These enzymes phosphorylate specific tyrosine residues on target proteins, leading to their activation and downstream signaling.
- **Activation of G protein-coupled receptors (GPCRs):** GPCRs activate heterotrimeric G proteins, which then activate effector enzymes such as phospholipase C (PLC).
- **Activation of phosphoinositide 3-kinase (PI3K):** PI3K phosphorylates phosphatidylinositol, generating signaling molecules that activate other downstream pathways.

3. **Transcriptional Activation:** Signal transduction pathways lead to the activation of transcription factors, such as NF-κB and AP-1, which translocate to the nucleus and regulate the expression of genes involved in neutrophil activation.

4. **Cellular Responses:** The upregulation of gene expression results in several functional changes in neutrophils:
- **Increased adhesion and chemotaxis:** Neutrophils express adhesion molecules, such as integrins, which allow them to adhere to the endothelium of blood vessels and migrate towards the site of inflammation.
- **Release of reactive oxygen species (ROS):** Neutrophils generate ROS, such as superoxide and hydrogen peroxide, which are potent antimicrobial agents.
- **Release of antimicrobial peptides:** Neutrophils release a variety of antimicrobial peptides, such as defensins and cathelicidins, which can directly kill pathogens.
- **Degranulation:** Neutrophils contain granules filled with enzymes and other cytotoxic molecules, which are released upon activation.

**Regulation of positive regulation of neutrophil activation:**

- **Negative feedback loops:** Several mechanisms exist to prevent excessive inflammation and ensure proper resolution of the immune response. These include the production of anti-inflammatory cytokines, such as IL-10, and the activation of inhibitory receptors, such as CD200R.
- **Apoptosis:** After activation, neutrophils undergo programmed cell death, preventing prolonged inflammation and tissue damage.

**Consequences of dysregulation:**

- **Chronic inflammation:** Uncontrolled neutrophil activation can contribute to chronic inflammation, leading to autoimmune diseases and other chronic conditions.
- **Immunodeficiency:** Defects in neutrophil activation can result in increased susceptibility to infections.

**Therapeutic implications:**

- **Anti-inflammatory drugs:** Targeting signaling pathways involved in neutrophil activation can be a therapeutic strategy for treating inflammatory diseases.
- **Immune modulators:** Modulating neutrophil function can be beneficial in certain autoimmune conditions or infections.

This description provides a comprehensive overview of the positive regulation of neutrophil activation, highlighting the key signaling pathways, cellular responses, and regulatory mechanisms involved. Understanding this complex process is essential for developing new therapeutic strategies for various inflammatory and infectious diseases.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Tumor necrosis factorA tumor necrosis factor that is encoded in the genome of human. [PRO:DNx]Homo sapiens (human)

Compounds (18)

CompoundDefinitionClassesRoles
mesalaminemesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols
non-steroidal anti-inflammatory drug
way 151693
pentoxifyllineoxopurine
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases.methoxybenzenes
roliprampyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
sulfasalazinesulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
bergeninbergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structuretrihydroxybenzoic acidmetabolite
marimastatmarimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.

marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary
hydroxamic acid;
secondary carboxamide
antineoplastic agent;
matrix metalloproteinase inhibitor
birb 796aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator
ganoderic acid atriterpenoid
ganoderiol fganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first sourcetriterpenoid
1-(phenylmethyl)benzimidazolebenzimidazoles
luteolin-7-glucosideluteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.

luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum
beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone
antioxidant;
plant metabolite
apigetrinapigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.

apigetrin: structure given in first source
beta-D-glucoside;
dihydroxyflavone;
glycosyloxyflavone;
monosaccharide derivative
antibacterial agent;
metabolite;
non-steroidal anti-inflammatory drug
calycosin-7-o-beta-d-glucopyranosidecalycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage.

calycosin-7-O-beta-D-glucoside: from Radix Astragali
4'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative
spd-304SPD-304: structure in first source
ganoderic acid fganoderic acid F: isolated from Ganoderma lucidum; structure in first sourcetriterpenoid
ganoderic acid c2ganoderic acid C2: from the fruiting body of Ganoderma; structure in first sourcetriterpenoid